Author Affiliations: Departments of Dermatology (Drs Baumann Conzett, Kolm, Kamarachev, Dummer, Braun, French, and Hofbauer) and Neurology (Drs Jelcic and Linnebank), Z ürich University Hospital, Z ürich, Switzerland.
The immunosuppressant drug FTY720 inhibits lymphocyte emigration from lymphoid organs.1 The phase III TRANSFORMS trial2 showed no melanomas in 420 patients treated with 1.25-mg/d FTY720, 3 melanomas in 429 patients treated with 0.5-mg/d FTY720, and no melanomas in 431 patients treated with interferon beta-1a.2 In the FREEDOMS trial3 over 24 months, 1 melanoma occurred in 429 patients treated with 1.25-mg/d FTY720, no melanomas in 425 patients treated with0.5-mg/d FTY720, and 1 melanoma in 418 patients taking placebo. A 3-year phase II study showed 1 melanoma in the placebo/FTY720 group after 25 months and 1 melanoma in the 1.25-mg/d FTY720 group after 36 months.
Conzett KB, Kolm I, Jelcic I, et al. Melanoma Occurring During Treatment With Fingolimod for Multiple Sclerosis: A Case Report. Arch Dermatol. 2011;147(8):991–992. doi:10.1001/archdermatol.2011.212
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: